Safety and activity of the TGFβ receptor i kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer

  1. Melisi, D.
  2. Oh, D.-Y.
  3. Hollebecque, A.
  4. Calvo, E.
  5. Varghese, A.
  6. Borazanci, E.
  7. Macarulla, T.
  8. Merz, V.
  9. Zecchetto, C.
  10. Zhao, Y.
  11. Gueorguieva, I.
  12. Man, M.
  13. Gandhi, L.
  14. Estrem, S.T.
  15. Benhadji, K.A.
  16. Lanasa, M.C.
  17. Avsar, E.
  18. Guba, S.C.
  19. Garcia-Carbonero, R.
Aldizkaria:
Journal for ImmunoTherapy of Cancer

ISSN: 2051-1426

Argitalpen urtea: 2021

Alea: 9

Zenbakia: 3

Mota: Artikulua

DOI: 10.1136/JITC-2020-002068 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus